ArticleJournal of cosmetic dermatology2026
Efficacy of Polynucleotide-Based Therapy in Atopic Dermatitis Management.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of Polynucleotide-Based Therapy in Atopic Dermatitis Management.Journal of cosmetic dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis (AD) is a chronic inflammatory skin disease characterized by persistent itching, dryness, redness, and recurrent eczematous lesions, significantly impacting patients' quality of life and psychological well-being. Despite various effective conventional treatments, innovative therapeutic approaches that simultaneously provide anti-inflammatory effects and enhanced skin hydration remain essential.
objectiveThis case-series study aimed to evaluate the clinical efficacy, patient satisfaction, and safety profile of polynucleotide (PN)-based injectable therapies in patients with AD.
methodsPatients with clinically diagnosed AD underwent intradermal injections of PN. Treatment outcomes were assessed by comparing standardized clinical photographs taken before and after the PN treatment, focusing on improvements in erythema, skin thickness, and overall skin hydration. Additionally, patient-reported outcomes, including reductions in itching, discomfort, and treatment satisfaction, were evaluated.
resultsPosttreatment evaluations demonstrated notable clinical improvements, including reduced erythema, decreased skin thickness, and enhanced skin hydration and elasticity. Patients consistently reported significant alleviation of itching and overall discomfort. Furthermore, high patient satisfaction and good adherence to treatment were observed, with no significant adverse events or side effects reported.
conclusionThis exploratory case series provides preliminary observations suggesting that PN-based injectable therapies may offer benefits for patients with AD, particularly in improving skin hydration, barrier function, and symptomatic relief. While positive outcomes were documented in all four cases, the absence of validated scoring systems, objective biophysical measures, long-term follow-up, and a control group limits the strength and generalizability of these findings. PN injections in this context remain off-label, and further prospective, controlled studies with larger, more diverse populations are essential to establish efficacy, safety, optimal dosing regimens, and durability of response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.